LivaNova shares are trading lower after the company's RECOVER clinical study did not meet its primary endpoint for the unipolar cohort, though statistical significance was achieved in select secondary endpoints.
Portfolio Pulse from Benzinga Newsdesk
LivaNova shares are trading lower after the company's RECOVER clinical study did not meet its primary endpoint for the unipolar cohort, though statistical significance was achieved in select secondary endpoints.
June 06, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
LivaNova shares are trading lower after the company's RECOVER clinical study did not meet its primary endpoint for the unipolar cohort, though statistical significance was achieved in select secondary endpoints.
The failure to meet the primary endpoint in the RECOVER clinical study is a significant setback for LivaNova, likely leading to a negative short-term impact on the stock price. However, the achievement of statistical significance in some secondary endpoints may mitigate the decline slightly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100